Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences Ltd., today announced encouraging topline results from its pivotal EPICS-III Phase 2(b)/3 clinical trial of Saroglitazar, a novel dual PPAR alpha/gamma agonist, for adult patients with Primary Biliary Cholangitis (PBC) who had an inadequate response or
Four Posters accepted at The Liver Meeting® 2022 Two Posters are awarded the “AASLD Presidential Poster Of Distinction”Ahmedabad, India November 03, 2022 Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), a discovery-driven, global lifesciences company today announced that four abstracts on Saroglitazar Mg will be
